Sep 2026
Abstract A133: CASPER: A Phase Ib trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer
A hallmark of PDAC is its ability to reprogram metabolism. A majority of PDAC tumors (50-80%) express low levels of asparagine synthetase (ASNS) rendering them dependent on extracellular asparagine. L-asparaginase (ASNase) depletes systemic asparagine to restrict tumor cell growth, but clinical trials of ASNase i...
Lyndsey Sandow, Adel Kardosh, Emerson Y. Chen et al.
· Cancer Research · 0 citations